Sarah Nestlehut, PharmD

Formulary Management Director Sr
Prime Therapeutics

Poster(s):

• (51) Economic and Clinical Impact of Dual Orexin Receptor Antagonists Versus Zolpidem in Medicare Part D Beneficiaries with Chronic Insomnia
  Wednesday, October 29, 2025